U.S. Markets closed

China Biologic Reports Financial Results for the First Quarter of 2019

--1Q19 Total Sales Up 15.4% YoY in USD terms, or 22.3% YoY in RMB terms;
Net Income Up 19.3% YoY to $37.7 Million;
Non-GAAP Adjusted Net Income Up 14.3% YoY in RMB terms --

BEIJING, May 10, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the first quarter of 2019.

First Quarter 2019 Financial Highlights

  • Total sales in the first quarter of 2019 increased by 22.3% in RMB terms and 15.4% in USD terms to $129.8 million from $112.5 million in the same quarter of 2018.
  • Gross profit increased by 8.6% to $85.6 million from $78.8 million in the same quarter of 2018. Gross margin decreased to 65.9% from 70.0% in the same quarter of 2018.
  • Income from operations increased by 12.8% to $44.0 million from $39.0 million in the same quarter of 2018. Operating margin decreased to 33.9% from 34.7% in the same quarter of 2018.
  • Non-GAAP adjusted income from operations increased by 10.5% in RMB terms and 4.2% in USD terms to $52.2 million from $50.1 million in the same quarter of 2018.
  • Net income attributable to the Company increased by 26.5% in RMB terms and 19.3% in USD terms, to $37.7 million from $31.6 million in the same quarter of 2018. Fully diluted earnings per share increased to $0.94 compared to $0.92 in the same quarter of 2018.
  • Non-GAAP adjusted net income attributable to the Company increased by 14.3% in RMB terms and 7.7% in USD terms to $44.5 million from $41.3 million in the same quarter of 2018. Non-GAAP adjusted earnings per share decreased to $1.11 from $1.21 in the same quarter of 2018.

"China Biologic achieved better-than-expected financial results for the first quarter, with growth in operating profit that exceeded expectations. Despite this welcome news, the challenging policy headwinds and heightened competition within the Chinese plasma industry persist and we maintain our overall outlook for the year," said Joseph Chow, Chairman of the China Biologic Board of Directors.

"This quarter's outperformance in terms of operating profit growth can be largely attributed to higher-than-expected sales of albumin. This was due to a temporary shortage of albumin supply in the market related to lower import volumes combined with increased plasma fractionation capability at our new Shandong facility launched last February. However, sales of IVIG products did not meet our expectations, due to reduced purchase volumes at many regional hospitals as mandated by government controls on healthcare spending. The performance of our placenta polypeptide product was largely in line with expectations, with sales down 50% year over year. As market prices decline for our major products, our gross margin continues to be negatively impacted. Although our prior efforts and investments towards improving our sales and marketing capabilities have been successful in broadening our sales channel coverage and reducing Guizhou Taibang's IVIG inventory, the prescription volumes of IVIG and certain high-unit-price coagulation products remain sluggish."

"We recently received Dr. Bing Li's resignation as CEO and also from the Board of Directors due to personal reasons. We thank Dr. Li for his contribution in helping China Biologic optimize our sales and marketing team and improve corporate governance. The Board has formed a search committee comprised of independent directors to seek a new CEO and in the interim has appointed me as the acting CEO."

"Looking ahead to the rest of the year, given the relatively fixed annual volume of our available plasma inventory and the oversold albumin volume in the first quarter, the overall albumin sales growth rate in the remaining quarters of this year will likely decelerate. Our new sales and marketing talent will leverage our expanded sales coverage in various channels to offer a variety of products, with renewed efforts towards improving the prescription volumes at regional hospitals and educating doctors about the benefits of IVIG, PCC and other coagulation factor products in treating patients across a wide range of clinical indications. We expect these efforts to help decrease our IVIG inventory position, which is currently above the normal level, both internally and with our distributors."

Share Repurchase Program

In late April 2019, the Company completed the share repurchase program previously authorized by its Board of Directors in 2018, repurchasing 1,074,376 shares at a total of $100 million.

In May 2019, the Company's Board of Directors authorized a new share repurchase program under which China Biologic may repurchase up to US$150 million worth of shares over the next 12 months.

The Company's repurchases may be made from time to time on the open market at prevailing market prices, in negotiated transactions off the market, in block trades or through other legally permissible means. The timing and extent of any purchases will depend upon market conditions, the trading price of its shares and other factors, and are subject to the restrictions relating to volume, price and timing under applicable law.

First Quarter 2019 Financial Performance 

Total sales in the first quarter of 2019 increased by 22.3% in RMB terms, or 15.4% in USD terms, to $129.8 million from $112.5 million in the same quarter of 2018.

Total sales for biopharmaceutical products (including plasma products and placenta polypeptide products) increased by 22.2% in RMB terms, or 15.2% in USD terms, to $116.5 million from $101.1 million in the same quarter of 2018, as a result of increases in the sales of human albumin products and coagulation factor products, which was partly offset by decreases in the sales of IVIG and placenta polypeptide products. For plasma products, total sales in the first quarter of 2019 increased by 35.8% in RMB terms, or 28.0% in USD terms, to $108.8 million from $85.0 million in the same quarter of 2018.

Total sales for biomaterial products in the first quarter of 2019 increased by 23.8% in RMB terms, or 16.7% in USD terms, to $13.3 million from $11.4 million in the same quarter of 2018, as a result of higher sales concentration in higher-unit-price artificial dura mater products.

During the first quarter of 2019, human albumin and IVIG products remained the Company's two largest sales contributors. Revenue from human albumin increased by 78.2% in RMB terms, or 68.0% in USD terms, from $33.8 million in the first quarter of 2018 to $56.8 million in the first quarter of 2019. Revenue from IVIG products decreased by 3.1% in RMB terms, or 8.8% in USD terms, from $31.8 million in the first quarter of 2018 to $29.0 million in the first quarter of 2019. As a percentage of total sales, sales from human albumin and IVIG products were 43.8% and 22.4%, respectively, in the first quarter of 2019.

The sales volume of human albumin products increased by 85.8% for the first quarter of 2019, primarily due to increased sales volumes in the distributor and pharmacy channels, supplemented by increased direct sales to hospitals and inoculation centers. The sales volume of IVIG products increased by 1.1% for the first quarter of 2019 as a result of increased sales through the distributor channel.

The average prices for human albumin and IVIG products decreased by 4.1% and 4.2%, respectively, in RMB terms in the first quarter of 2019 compared to the same quarter of 2018 because of higher sales volume in the distributor channel and lower prices to certain distributors reflecting intensified market competition for major plasma products. In USD terms, the average price for human albumin and IVIG products decreased by 9.5% and 9.7%, respectively, in the first quarter of 2019 compared to the same quarter of 2018.

Revenue from other immunoglobulin products increased by 6.6% in RMB terms, or 0.5% in USD terms in the first quarter of 2019 compared to the same quarter of 2018, reaching 10.1% of total sales as compared to 11.6% of total sales in the same quarter of 2018. The revenue increase was mainly attributable to increased sales volume of human tetanus immunoglobulin products.

Revenue from other plasma products, including human coagulation factor VIII, human prothrombin complex concentrate, and human fibrinogen products, increased by 64.2% in RMB terms, or 54.9% in USD terms, in the first quarter of 2019 compared to the same quarter of 2018, representing 7.6% of total sales in the first quarter of 2019. The growth mainly came from increased sales through the distributor channel.

Revenue from placenta polypeptide products decreased by 52.4% in USD terms for the first quarter of 2019 as compared to the same quarter of 2018, accounting for 5.9% of total sales compared to 14.3% of total sales in the first quarter of 2018, mainly in line with a decrease in sales volume as a result of the inclusion of placenta polypeptide products in regional adjuvant drug lists, which put a downward pressure on their prescription volume.

Cost of sales increased by 31.2% to $44.2 million in the first quarter of 2019 from $33.7 million in the same quarter of 2018. As a percentage of total sales, cost of sales increased to 34.1% from 30.0% in the same quarter of 2018, mainly because of decreased sales prices for most of the Company's plasma products, increased plasma collection costs, and increased depreciation expenses due to the launch of the Company's new facility in Shandong in February 2018.

Gross profit increased by 8.6% to $85.6 million in the first quarter of 2019 from $78.8 million in the same quarter of 2018. Gross margin was 65.9% and 70.0% in the first quarter of 2019 and 2018, respectively.

Total operating expenses in the first quarter of 2019 increased by $1.8 million, or 4.5%, to $41.6 million from $39.8 million in the same quarter of 2018. This increase mainly consisted of an increase of $3.2 million in general and administrative expenses, partially offset by a decrease of $2.0 million in selling expenses. As a percentage of total sales, total operating expenses decreased to 32.0% in the first quarter of 2019 from 35.4% in the same quarter of 2018.

Selling expenses in the first quarter of 2019 decreased by $2.0 million, or 9.7%, to $18.7 million from $20.7 million for the first quarter of 2018. As a percentage of total sales, selling expenses decreased to 14.4% for the first quarter of 2019 from 18.4% in the same quarter of 2018. The decrease in selling expenses is primarily due to a decrease in marketing and promotion expenses related to placenta polypeptide products, which is partly offset by increased selling expenses for plasma products.

General and administrative expenses in the first quarter of 2019 increased by $3.2 million, or 18.4%, to $20.6 million from $17.4 million in the same quarter of 2018. As a percentage of total sales, general and administrative expenses increased to 15.9% for the first quarter of 2019 from 15.5% for the same quarter of 2018. The increase in general and administrative expenses was mainly a combined result of the increased allowance for doubtful accounts receivable and increased depreciation expenses for the Company's new facility in Shandong, which was partially offset by the decrease in share-based compensation expenses.

Research and development expenses in the first quarter of 2019 increased by $0.6 million, or 35.3%, to $2.3 million from $1.7 million in the same quarter of 2018. In the first quarter of 2019 and 2018, the Company received government grants totaling $0.4 million and $0.1 million, respectively, and the Company recognized them as a reduction of the research and development expenses. Excluding this impact, research and development expenses increased by $0.9 million for the first quarter of 2019 from the same quarter of 2018. As a percentage of total sales, research and development expenses, excluding the impact of these recognized government grants, increased to 2.1% for 2019 from 1.6% compared to the same quarter of 2018.

Income from operations in the first quarter of 2019 increased by 19.4% in RMB terms, or 12.8% in USD terms, to $44.0 million from $39.0 million in the same quarter of 2018. Operating margin decreased to 33.9% in the first quarter of 2019 from 34.7% in the first quarter of 2018.

Income tax expense in the first quarter of 2019 increased by $1.2 million, or 17.9%, to $7.9 million from $6.7 million in the same period of 2018. The effective income tax rate was 15.0% and 15.1% for the first quarter of 2019 and 2018, respectively.

Net income attributable to the Company increased by 26.5% in RMB terms, or 19.3% in USD terms, to $37.7 million in the first quarter of 2019 from $31.6 million in the same period of 2018. Net margin increased to 29.1% in the first quarter of 2019 from 28.1% in the same period of 2018. Diluted net earnings per share increased to $0.94 in the first quarter of 2019 compared to $0.92 in the same period of 2018.

Non-GAAP adjusted income from operations increased by 10.5% in RMB terms, or 4.2% in USD terms, to $52.2 million in the first quarter of 2019 from $50.1 million in the same period of 2018.

Non-GAAP adjusted net income attributable to the Company increased by 14.3% in RMB terms and 7.7% in USD terms, to $44.5 million in the first quarter of 2019 from $41.3 million in the same period of 2018. Non-GAAP net margin decreased to 34.3% in the first quarter of 2019 from 36.7% in the same period of 2018. Non-GAAP adjusted net income per diluted share decreased to $1.11 in the first quarter of 2019 from $1.21 in the same period of 2018.

Non-GAAP adjusted income from operations for the first quarter of 2019 excludes $6.3 million in non-cash employee share-based compensation expenses, and $2.1 million in amortization expense of intangible assets and land use rights related to the acquisition of TianXinFu.

Non-GAAP adjusted net income and diluted earnings per share for the first quarter of 2019 exclude $5.5 million in non-cash employee share-based compensation expenses, and $1.4 million in amortization expense of intangible assets and land use rights related to the acquisition of TianXinFu.

As of March 31, 2019, the Company had $99.0 million in cash on hand and demand deposits, $653.8 million in time deposits, and $171.2 million in short term investments.

Net cash provided by operating activities for the first quarter of 2019 was $32.2 million as compared to $23.3 million for the same period of 2018. The $8.9 million increase in net cash provided by operating activities was a combined result of the increase in both net income and non-cash expenses, which mainly include depreciation expenses and allowance for doubtful accounts receivable.

Accounts receivable increased by $11.6 million during the first quarter of 2019 as compared to $15.5 million during the same period of 2018. The accounts receivable turnover days for plasma products increased to 100 days during the first quarter of 2019 from 84 days during the same period of 2018, reflecting longer credit terms to hospitals as a result of the nationwide implementation of healthcare reform measures and intensified competition in the distributor channel.

Inventories increased by $4.0 million in the first quarter of 2019, which was milder than the increase of $10.8 million in the same period of 2018, mainly comprised of increased raw material plasma both out-sourced and from the Company's own collection stations.

Net cash used in investing activities for the first quarter of 2019 was $214.7 million as compared to $135.5 million for the same period of 2018. During the first quarter of 2019, the Company paid $7.9 million for the acquisition of property, plant and equipment, intangible assets and land use rights, and the Company also purchased time deposits and short-term investments in the amount of $937.4 million. This was partly offset by $730.6 million from the maturity of time deposits and short term investments. Net cash used in investing activities in the first quarter of 2018 mainly consisted of $264.7 million payment for purchase of time deposits and short term investments, $11.3 million for the acquisition of property, plant and equipment, intangible assets, and land use rights, which was partly offset by $97.7 million cash received upon acquisition of TianXinFu and the maturity of $42.8 million time deposits and short term investments.

Net cash used in financing activities for the first quarter of 2019 was $60.0 million as compared to net cash provided by financing activities of $0.3 million for the same period of 2018. In the first quarter of 2019, $60.0 million was remitted to an investment bank by the Company to execute the previously approved share repurchase program on behalf of the Company. As of March 31, 2019, 415,356 shares had been repurchased at a total amount of $36.8 million with the remaining $23.2 million as down payment to the investment bank for further repurchases. Net cash provided by financing activities in the first quarter of 2018 represented proceeds of $0.3 million from stock options exercised.

Financial Outlook

The Company reiterates its forecast for the full year 2019. The company expects both non-GAAP adjusted income from operations and non-GAAP adjusted net income to increase by 4% to 6% in RMB terms over full year 2018 financial results.

This guidance does not factor in any potential foreign currency translation impact. Having previously adopted an exchange rate of approximately RMB6.59 = $1.00 based on weighted average quarterly exchange rates in 2018 in translating 2018 financial results, the Company expects that the total sales and non-GAAP adjusted net income in USD terms in 2019 could be affected by the foreign currency translation impact.

This guidance excludes potential acquisitions, and necessarily assumes no significant adverse product price changes during 2019. This forecast reflects the Company's current and preliminary views, which are subject to change.

Conference Call

The Company will host a conference call at 7:30 am Eastern Time on May 13, 2019, which is 7:30 pm Beijing Time on May 13, 2019, to discuss its first quarter 2019 results and answer questions from investors. Listeners may access the call by dialing: 

US:              

1 888 346 8982

International:      

1 412 902 4272

Hong Kong:      

800 905 945

China:         

400 120 1203

A telephone replay will be available one hour after the conclusion of the conference all through May 20, 2019. The dial-in details are:

US:              

1 877 344 7529

International:      

1 412 317 0088

Passcode:         

10131286

A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com.

About China Biologic Products Holdings, Inc.

China Biologic Products Holdings, Inc. (CBPO) is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosage forms of plasma products through its indirect majority-owned subsidiary, Shandong Taibang Biological Products Co., Ltd. and its wholly owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. Since the acquisition of TianXinFu (Beijing) Medical Appliance Co., Ltd. in 2018, China Biologic is also engaged in the sale of medical devices, primarily regenerative medical biomaterial products. The Company sells its products to hospitals, distributors and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com.

Non-GAAP Disclosure

This news release contains non-GAAP financial measures that exclude non-cash compensation expenses related to options and restricted shares granted to employees and directors under the Company's 2008 Equity Incentive Plan and amortization of acquired intangible assets and land use rights. To supplement the Company's unaudited consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of these items in this release. The Company's management believes that its presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. A reconciliation of the adjustments to GAAP results appears in the table accompanying this news release. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.

In addition, as the Company evaluates certain key items of its financial results on a local currency basis (i.e., in RMB) in addition to the reporting currency (i.e., in USD), this news release contains local currency information that eliminates the impact of fluctuations in foreign currency exchange rates. The Company believes that, given its operations primarily based in China, providing local currency information on such key items enhances the understanding of its financial results and evaluation of performance in comparison to prior periods. Changes in local currency percentages are calculated by comparing financial results denominated in RMB from period to period.

Safe Harbor Statement

This news release may contain certain "forward-looking statements" relating to the business of China Biologic Products Holdings, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein, are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "intend," "believe," "expect," "are expected to," "will," or similar expressions, and involve known and unknown risks and uncertainties. Among other things, the management's quotations and forecast of the Company's financial performance in this news release contain forward-looking statements. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect.

Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including, without limitation, quality of purchased source plasma, potential delay or failure to complete construction of new collection facilities, potential inability to pass government inspection and certification process for existing and new facilities, potential inability to achieve the designed collection capacities at the new collection facilities, potential inability to achieve the expected operating and financial performance, potential inability to find alternative sources of plasma, potential inability to increase production at permitted sites, potential inability to mitigate the financial consequences of a temporarily reduced raw plasma supply through cost cutting or other efficiencies, and potential additional regulatory restrictions on its operations and those additional risks and uncertainties discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contact:  

China Biologic Products Holdings, Inc.
Mr. Ming Yin
Senior Vice President
Email: ir@chinabiologic.com

The Foote Group
Mr. Philip Lisio
Phone: +86-135-0116-6560
Email: phil@thefootegroup.com

(Financial statements on the following pages)

CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME






For the Three Months Ended


March 31, 2019


March 31, 2018


USD


USD

Sales:

129,784,067


112,464,890

           Plasma products:




             Human Albumin

56,812,789


33,795,961

             Immunoglobulin products:




               Human Immunoglobulin for Intravenous Injection

29,044,180


31,785,221

               Other Immunoglobulin products

13,089,220


13,019,557

             Others

9,870,008


6,372,962

           Placenta Polypeptide

7,658,990


16,094,645

                       Biopharmaceutical products

116,475,187


101,068,346

           Artificial Dura Mater

12,314,033


9,943,983

           Others

994,847


1,452,561

                       Biomaterial products

13,308,880


11,396,544





Cost of sales

44,240,445


33,691,683

Gross profit

85,543,622


78,773,207





Operating expenses




           Selling expenses

18,728,259


20,695,215

           General and administrative expenses

20,597,560


17,387,075

           Research and development expenses

2,330,825


1,716,954

Income from operations

43,886,978


38,973,963





Other income (expenses)




            Equity in income of an equity method investee

593,030


1,068,045

            Interest expense

(63,777)


(67,564)

            Interest income

6,525,839


3,003,929

            Other income, net

1,600,376


1,285,063

Total other income, net

8,655,468


5,289,473





Income before income tax expense

52,542,446


44,263,436





Income tax expense

7,918,442


6,707,455





Net income

44,624,004


37,555,981





Less: Net income attributable to noncontrolling interest

6,931,898


5,970,904





Net income attributable to China Biologic Products Holdings, Inc.

37,692,106


31,585,077





Earnings per share of ordinary share: 




             Basic

0.94


0.93

             Diluted

0.94


0.92

Weighted average shares used in computation:




             Basic

39,331,954


33,150,695

             Diluted

39,412,441


33,338,470





Net income

44,624,004


37,555,981





Other comprehensive income:




Foreign currency translation adjustment, net of nil income taxes

24,316,421


31,793,225





Comprehensive income

68,940,425


69,349,206





Less: Comprehensive income attributable to noncontrolling interest

8,752,259


9,363,694





Comprehensive income attributable to China Biologic Products Holdings, Inc.

60,188,166


59,985,512

 

CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. AND SUBSIDIARIES


UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS









March 31, 2019


December 31, 2018



USD


USD

ASSETS 





Current Assets 





   Cash and cash equivalents


99,014,190


338,880,559

   Time deposits


653,776,239


537,478,040

   Short term investments


171,246,688


76,048,594

   Accounts receivable, net of allowance for doubtful accounts 


136,879,611


125,115,842

   Inventories 


251,949,296


243,295,512

   Prepayments and other current assets, net of allowance for doubtful accounts


56,706,504


36,369,275

      Total Current Assets 


1,369,572,528


1,357,187,822






Property, plant and equipment, net 


181,435,868


178,327,361

Intangible assets, net


52,381,256


53,258,871

Land use rights, net 


35,058,239


32,204,342

Equity method investment 


16,319,927


15,428,028

Prepayment in equity securities


-


10,812,893

Other investments


10,812,893


-

Loan receivable - non current


39,072,334


39,942,591

Goodwill


319,636,741


313,588,803

Other non-current assets 


11,969,205


9,227,970

           Total Assets 


2,036,258,991


2,009,978,681






LIABILITIES AND SHAREHOLDERS' EQUITY 





Current Liabilities 





   Accounts payable 


4,427,318


11,404,642

   Income tax payable 


12,978,577


11,010,347

   Other payables and accrued expenses 


91,105,696


99,933,793

      Total Current Liabilities 


108,511,591


122,348,782






Deferred income


2,754,860


2,824,212

Non-current income tax payable


26,899,038


26,899,038

Other liabilities 


14,921,225


13,203,485

           Total Liabilities 


153,086,714


165,275,517






Shareholders' Equity 





   Ordinary share:





      par value $0.0001;





      100,000,000 shares authorized;





      41,633,669 and 41,616,320 shares issued at March 31, 2019 and December 31, 2018, respectively;





      38,963,609 and 39,361,616 shares outstanding at March 31, 2019 and December 31, 2018, respectively


4,163


4,162

   Additional paid-in capital 


1,196,008,137


1,189,698,494

   Treasury share: 2,670,060 shares at March 31, 2019 and 2,254,704 at December31, 2018, respectively, at
cost


(93,206,049)


(56,425,094)

   Retained earnings


672,174,844


634,482,738

   Accumulated other comprehensive loss


(23,214,642)


(45,710,701)

            Total equity attributable to China Biologic Products Holdings, Inc. 


1,751,766,453


1,722,049,599






   Noncontrolling interest 


131,405,824


122,653,565






            Total Shareholders' Equity 


1,883,172,277


1,844,703,164






   Commitments and contingencies 


-


-






            Total Liabilities and Shareholders' Equity 


2,036,258,991


2,009,978,681

 

CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 








For the Three Months Ended



March 31,


March 31,



2019


2018



USD


USD

CASH FLOWS FROM OPERATING ACTIVITIES: 





Net income 


44,624,005


37,555,981

Adjustments to reconcile net income to net cash provided by operating activities:





Depreciation 


3,959,985


2,325,609

Amortization


2,439,384


2,404,758

Loss on disposal of property, plant and equipment


37,829


44,142

Fair value changes of short term investments


(836,538)


(1,285,063)

Allowance for doubtful accounts - accounts receivable, net


2,224,200


-

Reversal for doubtful accounts - prepayments and other receivables 


(19,560)


-

Deferred income tax benefit


(382,896)


(846,255)

Share-based compensation 


6,305,967


9,009,234

Equity in income of an equity method investee 


(593,030)


(1,068,045)

Change in operating assets and liabilities: 





Accounts receivable


(11,554,181)


(15,505,930)

Inventories


(3,952,734)


(10,766,490)

Prepayments and other current assets 


3,546,405


(4,582,769)

Other non-current assets


(550,055)


-

Accounts payable 


(5,544,331)


(1,942,878)

Income tax payable 


1,751,980


1,504,625

Other payables and accrued expenses 


(9,000,340)


6,618,643

Deferred income


(123,545)


(130,974)

Other liabilities 


(166,909)


-

Net cash provided by operating activities 


32,165,636


23,334,588






CASH FLOWS FROM INVESTING ACTIVITIES:





Cash acquired from acquisition of TianXinFu


-


97,702,278

Purchase of time deposits


(743,412,316)


(84,828,600)

Proceeds from maturity of time deposits


629,307,453


3,000,000

Purchase of short term investments


(193,967,620)


(179,855,473)

Proceeds from maturity of short term investments


101,281,030


39,772,069

Payment for property, plant and equipment


(5,468,377)


(11,048,396)

Payment for intangible assets and land use rights


(2,453,524)


(255,664)

Proceeds from disposal of property, plant and equipment 


436


10,722

Net cash used in investing activities 


(214,712,918)


(135,503,064)






CASH FLOWS FROM FINANCING ACTIVITIES: 





Proceeds from stock option exercised 


3,678


339,411

Payment to an investment bank for share repurchase


(60,000,000)


-

Net cash (used in)/ provided by financing activities 


(59,996,322)


339,411






EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH AND CASH
EQUIVALENTS


2,677,235


10,697,430






NET DECREASE  IN CASH AND CASH EQUIVALENTS


(239,866,369)


(101,131,635)






Cash and cash equivalents at beginning of period 


338,880,559


219,336,848






Cash and cash equivalents at end of period


99,014,190


118,205,213






Supplemental cash flow information 





Cash paid for income taxes 


6,687,364


6,352,407

Noncash investing and financing activities: 





Acquisition of property, plant and equipment included in payables 


2,113,697


5,389,336

Set-off loan receivable against accounts payable


1,636,952


-

Fair value of noncash assets acquired and liabilities assumed in acquisition of TianXinFu

-


337,186,892

Land use right acquired with prepayments made in prior periods 


2,689,467


-

Share repurchase using the prepayment to an investment bank


36,780,955


-

 

CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES 










For the Three Months Ended




March 31,


March 31,




2019


2018




USD


USD

Income from Operations



43,886,978


38,973,963

Non-cash employee share-based compensation


6,305,967


9,009,234

Amortization of acquired intangible assets and land use rights


2,055,032


2,157,302

Adjusted Income from Operations - Non GAAP


52,247,977


50,140,499







Net Income Attributable to the Company


37,692,106


31,585,077

Non-cash employee share-based compensation


5,450,091


8,262,637

Amortization of acquired intangible assets and land use rights


1,397,422


1,466,965

Adjusted Net Income Attributable to the Company - Non GAAP


44,539,619


41,314,679

Diluted EPS - Non GAAP



1.11


1.21







Weighted average number of shares used in computation of Non GAAP diluted EPS


39,412,441


33,338,470

 

Cision

View original content:http://www.prnewswire.com/news-releases/china-biologic-reports-financial-results-for-the-first-quarter-of-2019-300847980.html